Co-Management Strategies in CKD: The Role of the Pharmacist in Counseling Patients

CMEO BriefCase

Premiere Date: Friday, November 5, 2021

This activity will offer CE credit for:

  1. Pharmacy (acpe)


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date: Saturday, November 5, 2022

Begin Activity Now

Faculty


Dhiren K. Patel, PharmD, CDCES, BC-ADM
Dhiren K. Patel, PharmD, CDCES, BC-ADM (Moderator)
Adjunct Associate Professor of Pharmacy Practice
School of Pharmacy at Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacy Specialist
Boston, MA

Robert S. Busch, MD, FACE
Robert S. Busch, MD, FACE 
Director of Clinical Research
Community Endocrine Group
Albany Med Faculty Practice
Albany, NY

Statement of Need

Chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM) is associated with poorer health-related quality of life (HRQoL), significant disability, need for renal replacement therapy (dialysis) in end stage disease, and increased renal and CV-associated mortality. Unfortunately, this disease is often silent until late stage, displaying few early symptoms, and as a result, only about 10% of patients with mild or moderate disease even know that they have CKD. Literature shows that about 40% of patients with T2DM will go on to develop CKD. As the burden of diabetes-associated CVD, renal, and other complications have become more widely acknowledged, it has become clear that pharmacists are an untapped resource to make patients aware of guideline-recommended screenings that can detect CKD early, provide and make recommendations to providers to optimize drug therapy, and counsel patients. It is imperative that pharmacists remain up-to-date on current and emerging treatments that may delay CKD progression and reduce the risk of CV events.

In this CMEO BriefCase, expert faculty will utilize a patient case to show the pathophysiological features of CKD and assess new efficacy and safety data for current and emerging therapies for CKD in patients with T2DM with a goal of improving co-management strategies.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Describe the pathophysiological features of CKD giving rise to renal, CV, and mortality risks in patients with CKD and T2DM, despite optimized management according to current standards of care (SOC).
  • Assess new efficacy and safety data for current and emerging therapies for CKD patients with T2DM.

Financial Support

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.

Target Audience

Pharmacists

Credit Information

Jointly Accredited Provider
JA

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Pharmacists (ACPE):
This knowledge-based activity is approved for .5 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-21-085-H04-P).

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Patel reports that he is on the speakers bureau for Abbott; Amarin Corporation; AstraZeneca; Bayer; Boehringer Ingelheim; Dexcom, Inc.; Lilly; Novo Nordisk; Xeris Pharmaceuticals, Inc.; and Zealand Pharma.

Dr. Busch reports that he receives research support from Afimmune; Amarin Corporation; Bayer; Lilly; Kowa Pharmaceuticals America, Inc.; and Novo Nordisk. He reports that he is on the speakers bureau for Amgen Inc.; AstraZeneca; Bayer; Lilly; and Novo Nordisk.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Julie Strickland, PharmD (planning committee) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Heather Lewin, MAT (planning committee) has no disclosures to report.

Kathleen Blake, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.

CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

BC-059-110521-61